Alzamend Neuro (ALZN) News Today $2.46 +0.02 (+0.82%) Closing price 08/27/2025 04:00 PM EasternExtended Trading$2.43 -0.03 (-1.22%) As of 08/27/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALZN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Ascendiant Capital Markets Has Lowered Expectations for Alzamend Neuro (NASDAQ:ALZN) Stock PriceAugust 22, 2025 | americanbankingnews.comAlzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Up 79.6% in JulyAugust 19, 2025 | americanbankingnews.comMilton C. Ault III Sells 29,449 Shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) StockAugust 2, 2025 | insidertrades.comAlzamend Neuro Increases Common Stock Through ConversionAugust 1, 2025 | tipranks.comInsider Selling: Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Sells 8,311 Shares of StockJuly 30, 2025 | insidertrades.comAlzamend Neuro to Present at the 2025 Military Health System Research SymposiumJuly 28, 2025 | globenewswire.comAlzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton C. Ault III Sells 9,621 SharesJuly 26, 2025 | insidertrades.comAlzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical ProgramsJuly 23, 2025 | globenewswire.comAlzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of ScheduleJune 16, 2025 | globenewswire.comAlzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s ThrilledMay 29, 2025 | msn.comAlzamend Neuro Stock Doubles After Dosing of First Patient in Clinical TrialMay 29, 2025 | marketwatch.comAlzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General HospitalMay 29, 2025 | globenewswire.comAlzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General HospitalMay 19, 2025 | globenewswire.comAlzamend Neuro, Inc.: Alzamend Neuro Announces Reverse Stock SplitMay 16, 2025 | finanznachrichten.deAlzamend Neuro, Inc.May 15, 2025 | cnn.comAlzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General HospitalMay 13, 2025 | globenewswire.comAlzamend Neuro announces reverse stock split to meet Nasdaq requirementsMay 9, 2025 | investing.comAlzamend Neuro Announces Reverse Stock SplitMay 8, 2025 | globenewswire.comAlzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General HospitalMay 7, 2025 | globenewswire.comIs Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.comAlzamend Neuro CFO David Katzoff acquires $5,048 in common stockMarch 26, 2025 | investing.comAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General HospitalMarch 25, 2025 | globenewswire.comAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General HospitalMarch 18, 2025 | globenewswire.comAlzamend Neuro files to sell 75.775M shares of common stock for holdersMarch 14, 2025 | markets.businessinsider.comAlzamend Neuro announces initiation of Phase II trial of AL001March 12, 2025 | markets.businessinsider.comAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General HospitalMarch 11, 2025 | globenewswire.comAlzamend Neuro Announces Bylaws Amendment and New Stock SeriesMarch 5, 2025 | investing.comAlzamend Neuro announces initiation date of Phase II trial of AL001March 4, 2025 | markets.businessinsider.comAlzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General HospitalMarch 4, 2025 | globenewswire.comAlzamend Neuro (ALZN) Gets a Hold from Maxim GroupFebruary 26, 2025 | markets.businessinsider.comAlzamend Neuro announces initiation data of Phase II trial of AL001February 26, 2025 | markets.businessinsider.comAlzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General HospitalFebruary 25, 2025 | globenewswire.comAlzamend Neuro announces completion of head coil by Tesla Dynamic CoilsFebruary 19, 2025 | markets.businessinsider.comAlzamend Neuro to Present at the Sequire Investor SummitJanuary 15, 2025 | stockhouse.comAlzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpoDecember 19, 2024 | finance.yahoo.comAlzamend Neuro says net cash gained by financing activity $8.3MDecember 12, 2024 | markets.businessinsider.comEXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug PotentialNovember 19, 2024 | finance.yahoo.comAlzamend Neuro regains Nasdaq compliance with equity ruleOctober 17, 2024 | uk.investing.comAlzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer'sOctober 16, 2024 | stockhouse.comEXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer'sOctober 16, 2024 | msn.comAlzamend Neuro Regains Compliance with Nasdaq Listing StandardsOctober 15, 2024 | finance.yahoo.comAlzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare ConferenceOctober 10, 2024 | finance.yahoo.comAlzamend Neuro Issues Letter to StockholdersAugust 26, 2024 | finance.yahoo.comAlzamend Neuro Shares Rise on Partnership for PTSD Treatment Mid-Stage StudyAugust 20, 2024 | marketwatch.comAlzamend Neuro (NASDAQ:ALZN) Stock, Short Interest ReportAugust 20, 2024 | benzinga.comAlzamend Neuro (NASDAQ:ALZN) Stock Quotes, Forecast and News SummaryAugust 20, 2024 | benzinga.comAlzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: DetailsAugust 20, 2024 | msn.comAlzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive DisorderAugust 12, 2024 | theglobeandmail.comAlzamend Neuro partners with Mass General for Phase II trialAugust 7, 2024 | uk.investing.comAlzamend Neuro director buys shares worth $93August 3, 2024 | investing.com Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALZN Media Mentions By Week ALZN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALZN News Sentiment▼0.170.99▲Average Medical News Sentiment ALZN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALZN Articles This Week▼31▲ALZN Articles Average Week Get the Latest News and Ratings for ALZN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Alzamend Neuro and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Tenax Therapeutics News Today Cadrenal Therapeutics News Today CASI Pharmaceuticals News Today Rein Therapeutics News Today Medicus Pharma News Today Reviva Pharmaceuticals News Today Trinity Biotech News Today FibroBiologics News Today Enlivex Therapeutics News Today Rallybio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALZN) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access